GlassScriptPhysician profile
Caitlin Joan Colescott
NPI 1114635182
$2,264.96
in general payments reported to CMS, 2019-2025
25 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.88 · 2023: $542 · 2024: $374 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $327.71 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $306.76 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $285.92 | 2023-2025 | Rexulti, Abilify Maintena |
| Viiv Healthcare Company | $243.48 | 2023-2025 | Apretude, Dovato, Cabenuva |
| Vanda Pharmaceuticals INC. | $205.01 | 2025 | Fanapt, Hetlioz |
| Amgen INC. | $139.05 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $117.36 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Sumitomo Pharma America, INC. | $77.79 | 2023-2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $70.34 | 2022-2025 | Austedo Xr, Austedo Xr |
| Astellas Pharma US INC | $63.76 | 2025 | Veozah |
| Novo Nordisk INC | $59.05 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.30 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Lundbeck LLC | $56.88 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.92 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $33.37 | 2025 | Symbravo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $24.66 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $21.79 | 2023 | Spravato |
| Hologic Sales and Service, LLC | $18.75 | 2023 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $18.33 | 2024 | Pifeltro, Delstrigo, Dificid |
| Antares Pharma, INC. | $18.20 | 2024 | Xyosted |
| Mylan Specialty L.P. | $17.25 | 2024 | Yupelri |
| Indivior INC. | $16.73 | 2023 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2024 | Jardiance |
| Dexcom, INC. | $13.89 | 2023 | Dexcom G6 Transmitter |
| Organon LLC | $13.34 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Colescott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.